What specific pharmaceutical ingredient assets is Evonik selling to ProChem, and where are they located?

Evonik is selling selected production assets for pharmaceutical ingredients from its Hanau site in Germany to ProChem Group. These assets are distinct from its Hanau-based GMP facility for advanced pharmaceutical lipids used in RNA therapeutics, which will continue operating to supply clinical and small-scale commercial quantities.

Why is Evonik divesting these assets, and how does this align with its broader healthcare strategy?

Evonik is streamlining its healthcare asset footprint to focus investment and growth on core areas including advanced oral and injectable drug delivery technologies, precision biosolutions (e.g., lipids for mRNA and gene delivery), and advanced cell-culture ingredients. As stated by Guido Skudlarek, head of the healthcare business line, refining focus and aligning assets enables Evonik to deliver more strongly where it creates the highest value for customers.

Evonik Sells Pharma Ingredient Assets from German Site to ProChem

Jun 19, 2026

Evonik Industries has agreed to sell selected pharmaceutical ingredient production assets at its Hanau site to contract manufacturer ProChem Group. The move aligns with Evonik's strategy to streamline its healthcare business and focus on core drug delivery technologies.

chemweek

2026-03-10

Evonik Maintains 2026 Profit Forecast

2026-04-28

Evonik to supply membrane technology to bioenergy firm in Malaysia

2026-05-13

Evonik Partners with MTCO for Biogas Purification

2026-05-27

Evonik partners with university in Mexico on solutions for mining industry

2026-06-18

Evonik to Cut 3,200 More Jobs, Discontinue Polyester Business